ClinicalTrials.gg
CompletedNCT02712047Updated Aug 28, 2018Results posted

A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.

A Phase 2 interventional study of Fluticasone furoate (FF) (100 mcg) and Vilanterol (VI) (25 mcg) in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-28.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
29th of 40
28 · median 102
Started
2016
the only one that year
Phase 2
12 of 40
none open now
Registered
30th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 29th largest by enrollment, is the only one that started in 2016, is one of 12 in phase 2, and was the 30th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway inflammation marker.

In this randomised, double blind, placebo-controlled, two-period, crossover repeat dose study, the duration of action of fluticasone furoate (FF) will be determined by monitoring the return of FeNO levels to baseline, following the treatment with FF/vilanetrol (VI) in asthmatic subjects.

Subjects who meet the eligibility criteria will participate in the following two treatment periods: FF/VI 100/25 mcg once-daily and placebo once-daily. Approximately 28 subjects will be enrolled in order to achieve 24 evaluable subjects. A 2-week treatment period will be followed by a 21-day monitoring/washout period before crossing over to the next treatment period. Total duration of each subject will be a maximum of 21 weeks. FeNO will be monitored up to 21 days after treatment with FF/VI together with FEV1 (up to 7 days).

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Fluticasone furoate/vilanterol
  • Asthma
  • fraction of exhaled nitric oxide
  • cross-over
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of subject: Between 18 and 65 years of age inclusive, at the time of signing the .
  • A doctor diagnosis of asthma for at least 6 months prior to the start of the study.
  • Severity of disease: A screening pre-bronchodilator (FEV1) >=60% of predicted values, which will be based upon NHANES III
  • Reversibility of disease: Demonstrated presence of reversible airway disease at screening (repeat testing of eligibility can be undertaken following the screening visit up to Day -7) OR The presence of reversible airways disease can have been demonstrated historically within 6 months of the screening visit. Reversible airway disease is defined as increase in FEV1 of >=12% over baseline and an absolute change of >=200 mL within 30 minutes following 4 inhalations of albuterol/salbutamol inhalation aerosol/spacer (or equivalent nebulised treatment with albuterol/salbutamol solution).
  • Current Therapy: Short-acting beta2-agonists (SABA) prescribed for at least 12 weeks prior to screening. No inhaled (ICS), long-actint beta2-receptor agonist (LABA), long acting muscarinic anatagonist (LAMA), leukotriene receptor antagonist (LTRA) therapy for three months prior to the start of the study.
  • Non-smoker or ex-smoker (no smoking in previous 12 weeks, ≤10 pack years).
  • Screening and Day -7 AM fraction of inhaled nitric oxide (FeNO) values > 40ppb. Both screening and Day -7 AM FeNO values for treatment Period 1 need to be > 40ppb for the subject to be eligible.
  • Bodyweight and : Bodyweight >=50 kg and body mass index (BMI) within the range 18.0 40.0 kg/m2 (inclusive)
  • Male OR Female:
  • Females: A female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin [hCG[ test), not lactating, and at least one of the following conditions applies: Non- defined as:
  • Pre-menopausal females reporting one of the following:

Tubal ligation Hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion Hysterectomy Bilateral Oophorectomy

  • defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause [refer to laboratory reference ranges for confirmatory levels]). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
  • Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication and until after the last dose of study medication and completion of the follow-up visit
  • The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • A history of life-threatening asthma, which is defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years
  • Other significant pulmonary diseases to include (but not limited to): pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma.
  • Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management OR in the opinion of the Investigator, is expected to affect the subject's asthma status OR the subject's ability to participate in the study. However, subjects can be rescreened to allow for an adequate time period (of at least 4 weeks) between resolution of the infection and the date of randomisation.
  • Asthma Exacerbation: Any asthma exacerbation requiring oral within 12 weeks of screening or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to screening.
  • Pre-defined concomitant medications and restrictions of nitrate-rich foods
  • Tobacco Use: Current smokers or a smoking history of >=10 pack years. A subject may not have used any inhaled tobacco products in 12 weeks preceding the screening visit.
  • Previous Participation: Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Other concurrent Diseases/Abnormalities: A subject has any , uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the study results if the condition/disease exacerbated during the study.
  • The list of additional excluded conditions/diseases includes, but is not limited to the following:
  • Congestive heart failure-Known aortic aneurysm
  • Clinically significant coronary heart disease-Clinically significant cardiac arrhythmia
  • Stroke within 3 months of Visit 1-Uncontrolled hypertension
  • Recent or poorly controlled peptic ulcer-Haematologic, hepatic, or renal disease
  • Immunologic compromise-Current
  • Tuberculosis (current or untreated)-Cushing's disease
  • Addison's disease-Uncontrolled diabetes mellitus
  • Liver cirrhosis-Systemic Lupus Erythematosus
  • Uncontrolled thyroid disorder-Recent history of drug or alcohol abuse
  • Oropharyngeal examination: A subject will not be eligible if he/she has clinical visual evidence of oral candidiasis at screening.
  • Pregnancy and Lactating Females:
  • Pregnant females as determined by positive serum hCG test at screening or by positive urine hCG test prior to dosing.
  • Lactating females
  • Allergies:
  • Milk Protein Allergy: History of severe milk protein allergy.
  • Drug Allergy: Any adverse reaction including immediate or delayed to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the Dry Powder Inhaler (DPI) (i.e., lactose or magnesium stearate).
  • Historical Allergy: History of drug or other allergy that, in the opinion of investigator or GSK Medical Monitor, contraindicates their participation
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg

    Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period

    Drug: Fluticasone furoate (FF) (100 mcg) · Drug: Vilanterol (VI) (25 mcg)

  • Placebo comparator
    Placebo

    Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period

    Drug: Placebo

Interventions

  • First blister strip contains FF blended with lactose, 100 mcg per blister

  • Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister

  • DrugPlacebo

    Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI

    FeNO is non-invasive marker of airway inflammation in asthma participants. It was measured by the participants, using Niox Vero device at AM (pre-dose) and PM on Day -7 and all way through Day 29 of each TP. The FeNO measurements were done over time following stop of repeat dose treatment with FF/VI. Change from Baseline was measured as ratio of post-dose visit value to Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline defined as the mean of Baseline across periods for each participant. Period level Baseline defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Summary of ratio from Baseline for exhaled nitric oxide reported as Geometric mean and Geometric coefficient of Variation. NA indicates data was not available.

    Time frame: Baseline and up to Day 29 in each treatment period

Secondary outcomes

  1. Change From Baseline in FeNO Over the FF/VI Treatment Period

    In participants with asthma the FeNO is a non-invasive marker of airway inflammation. The FeNO was measured by the participants AM (pre-dose) and PM on Day -7 and all the way through Day 29 of each treatment period. The measurements were recorded using Niox Vero device provided at the site. These FeNO measurements were done throughout the treatment period. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.

    Time frame: Baseline and up to Day 29 in each treatment period

  2. Change From Baseline in Peak Expiratory Flow (PEF) During Treatment and Following Cessation of Repeat Dose Treatment With FF/VI

    The PEF is a lung function evaluation assessed using a PEF meter. It was defined as the maximum amount of air exhaled during forced exhalation with lungs fully inflated. For PEF measurements the best of the 3 recordings were recorded AM and PM (i.e every 12 hours), from Day-7 through to Day 29 of TP1, and then from Day 1 of TP2 through to the (29). Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.

    Time frame: Baseline and up to Day 29 in TP1; Baseline and up to follow up (Day 29) in TP2

  3. Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Pre-treatment and for up to 7 Days After Cessation of Repeat Dose Treatment With FF/VI

    FEV1 is defined as the maximal amount of air which can be exhaled forcefully in one second. Three technically acceptable FEV1 measurements were made using a spirometer, and were measured on pre-dose on Day 1, taken pre-dose on Day 14 and every morning and evening until Day 19, and in the morning on Day 21. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant.

    Time frame: Baseline every morning and evening until Day 21 of each treatment period

07

Results

Posted Aug 28, 2018

Participant flow

This was a randomized, double blind, placebo-controlled, two-period, crossover repeat dose study in adult participants with asthma. The study was conducted from 29 April 2016 to 21 February 2017, at a single site in New Zealand.

Treatment Period 1 (35 Days)
Participant flow — Treatment Period 1 (35 Days)
MilestoneFluticasone Furoate/Vilanterol (FF/VI) Followed by PlaceboPlacebo Followed by FF/VI
Started1413
Completed1413
Not completed00
Washout Period (21 Days)
Participant flow — Washout Period (21 Days)
MilestoneFluticasone Furoate/Vilanterol (FF/VI) Followed by PlaceboPlacebo Followed by FF/VI
Started1413
Completed1413
Not completed00
Treatment Period 2 (35 Days)
Participant flow — Treatment Period 2 (35 Days)
MilestoneFluticasone Furoate/Vilanterol (FF/VI) Followed by PlaceboPlacebo Followed by FF/VI
Started1413
Completed1413
Not completed00

Outcome measures

PrimaryChange From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI

FeNO is non-invasive marker of airway inflammation in asthma participants. It was measured by the participants, using Niox Vero device at AM (pre-dose) and PM on Day -7 and all way through Day 29 of each TP. The FeNO measurements were done over time following stop of repeat dose treatment with FF/VI. Change from Baseline was measured as ratio of post-dose visit value to Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline defined as the mean of Baseline across periods for each participant. Period level Baseline defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Summary of ratio from Baseline for exhaled nitric oxide reported as Geometric mean and Geometric coefficient of Variation. NA indicates data was not available.

Time frame:
Baseline and up to Day 29 in each treatment period
Reported as:
Geometric mean · Ratio of exhaled Nitric Oxide
Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI
Ratio of exhaled Nitric OxidePlaceboFF/VI 100/25mcg
Day 1, AM (n=27,27)1.042 ± 31.54990.371 ± 47.3672
Day 1, PM (n=27,27)0.985 ± 26.47850.321 ± 51.5233
Day 2, AM (n=27,27)1.012 ± 27.30170.373 ± 71.6824
Day 2, PM (n=27,27)0.957 ± 26.33280.346 ± 52.6225
Day 3, AM (n=27,27)0.987 ± 24.61020.442 ± 60.8203
Day 3, PM (n=27,27)0.922 ± 23.67050.417 ± 51.1903
Day 4, AM (n=27,27)1.007 ± 34.92350.536 ± 60.5532
Day 4, PM (n=27,27)0.857 ± 23.79720.484 ± 48.1593
Day 5, AM (n=27,27)0.834 ± 24.45720.515 ± 53.5926
Day 5, PM (n=26,26)0.734 ± 27.13080.473 ± 46.6144
Day 6, AM (n=26,26)0.794 ± 31.59240.525 ± 50.7361
Day 6, PM (n=24,26)0.783 ± 30.82000.470 ± 43.8128
Day 7, AM (n=27,27)0.826 ± 31.46760.484 ± 49.0454
Day 7, PM (n=25,25)0.774 ± 32.74730.487 ± 49.9617
Day 8, AM (n=25,27)0.830 ± 40.77730.554 ± 47.5854
Day 8, PM (n=27,26)0.834 ± 30.40300.545 ± 42.1101
Day 9, AM (n=27,27)0.935 ± 35.75830.594 ± 45.0429
Day 9, PM (n=27,27)0.924 ± 32.13140.607 ± 46.3872
Day 10, AM (n=24,26)1.022 ± 34.47400.658 ± 41.3710
Day 10, PM (n=27,27)0.989 ± 35.10660.660 ± 41.4832
Day 11, AM (n=26,26)1.092 ± 37.71420.756 ± 40.9942
Day 11, PM (n=27,27)1.029 ± 28.66180.723 ± 45.9281
Day 12, AM (n=27,27)1.028 ± 29.96670.717 ± 42.8654
Day 12, PM (n=27,27)1.004 ± 28.56730.691 ± 43.1839
Day 13, AM (n=27,25)1.068 ± 34.00900.744 ± 38.4939
Day 13, PM (n=25,25)0.955 ± 40.29450.739 ± 39.5506
Day 14, AM (n=26,27)1.008 ± 45.53190.770 ± 43.7613
Day 14, PM (n=25,26)0.955 ± 45.57680.634 ± 76.0516
Day 15, AM (n=26,26)0.977 ± 51.55230.731 ± 40.4602
Day 15, PM (n=25,25)0.940 ± 42.36600.700 ± 48.1949
Day 16, AM (n=26,27)1.029 ± 51.18760.727 ± 44.7703
Day 16, PM (n=26,27)1.019 ± 38.16900.718 ± 50.7656
Day 17, AM (n=25,26)1.049 ± 40.14950.770 ± 44.3320
Day 17, PM (n=18,16)0.967 ± 38.47310.765 ± 59.4286
Day 18, AM (n=17,14)0.935 ± 39.04740.724 ± 54.2082
Day 18, PM (n=14,10)0.926 ± 39.24700.619 ± 58.6249
Day 19, AM (n=14,10)1.015 ± 42.22500.722 ± 51.2962
Day 19, PM (n=12,6)0.911 ± 30.69110.571 ± 48.1910
Day 20, AM (n=12,6)0.958 ± 43.00560.667 ± 45.5449
Day 20, PM (n=7,5)0.828 ± 39.65620.588 ± 54.7676
Day 21, AM (n=7,6)0.892 ± 35.85310.743 ± 54.8750
Day 21, PM (n=7,5)0.934 ± 40.40760.637 ± 63.2223
Day 22, AM (n=6,5)0.845 ± 45.87540.705 ± 82.0353
Day 22, PM (n=6,5)0.822 ± 43.08010.622 ± 75.8988
Day 23, AM (n=7,5)0.925 ± 51.48960.749 ± 76.0176
Day 23, PM (n=2,1)0.898 ± 116.91081.000 ± NA
Day 24, AM (n=2,1)0.914 ± 130.03751.144 ± NA
Day 24, PM (n=1,1)0.671 ± NA0.911 ± NA
Day 25, AM (n=1,0)0.548 ± NA—
Day 26, PM (n=0,1)—0.989 ± NA
Day 28, AM (n=0,1)—1.044 ± NA
Day 28, PM (n=0,1)—0.767 ± NA
Day 29, AM (n=0,1)—0.911 ± NA
Statistical analysis
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.36 · 95% CI 0.31 to 0.43Ratio of FF/VI 100/25mcg versus (Vs) Placebo for Day 1, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.33 · 95% CI 0.28 to 0.39Ratio of FF/VI 100/25mcg Vs Placebo for Day 1, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.38 · 95% CI 0.32 to 0.45Ratio of FF/VI 100/25mcg Vs Placebo for Day 2, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.37 · 95% CI 0.31 to 0.44Ratio of FF/VI 100/25mcg Vs Placebo for Day 2, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.46 · 95% CI 0.39 to 0.54Ratio of FF/VI 100/25mcg Vs Placebo for Day 3, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.47 · 95% CI 0.40 to 0.56Ratio of FF/VI 100/25mcg Vs Placebo for Day 3, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.56 · 95% CI 0.47 to 0.66Ratio of FF/VI 100/25mcg Vs Placebo for Day 4, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.58 · 95% CI 0.49 to 0.69Ratio of FF/VI 100/25mcg Vs Placebo for Day 4, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.63 · 95% CI 0.53 to 0.75Ratio of FF/VI 100/25mcg Vs Placebo for Day 5, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.67 · 95% CI 0.57 to 0.80Ratio of FF/VI 100/25mcg Vs Placebo for Day 5, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.67 · 95% CI 0.56 to 0.80Ratio of FF/VI 100/25mcg Vs Placebo for Day 6, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.62 · 95% CI 0.52 to 0.74Ratio of FF/VI 100/25mcg Vs Placebo for Day 6, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.60 · 95% CI 0.51 to 0.71Ratio of FF/VI 100/25mcg Vs Placebo for Day 7, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.62 · 95% CI 0.52 to 0.74Ratio of FF/VI 100/25mcg Vs Placebo for Day 7, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.69 · 95% CI 0.58 to 0.81Ratio of FF/VI 100/25mcg Vs Placebo for Day 8, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.68 · 95% CI 0.57 to 0.80Ratio of FF/VI 100/25mcg Vs Placebo for Day 8, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.66 · 95% CI 0.56 to 0.78Ratio of FF/VI 100/25mcg Vs Placebo for Day 9, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.68 · 95% CI 0.57 to 0.80Ratio of FF/VI 100/25mcg Vs Placebo for Day 9, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.66 · 95% CI 0.55 to 0.78Ratio of FF/VI 100/25mcg Vs Placebo for Day 10, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.68 · 95% CI 0.58 to 0.81Ratio of FF/VI 100/25mcg Vs Placebo for Day 10, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.73 · 95% CI 0.61 to 0.86Ratio of FF/VI 100/25mcg Vs Placebo for Day 11, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.73 · 95% CI 0.61 to 0.86Ratio of FF/VI 100/25mcg Vs Placebo for Day 11, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.72 · 95% CI 0.61 to 0.85Ratio of FF/VI 100/25mcg Vs Placebo for Day 12, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.71 · 95% CI 0.60 to 0.84Ratio of FF/VI 100/25mcg Vs Placebo for Day 12, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.72 · 95% CI 0.61 to 0.86Ratio of FF/VI 100/25mcg Vs Placebo for Day 13, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.78 · 95% CI 0.66 to 0.93Ratio of FF/VI 100/25mcg Vs Placebo for Day 13, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.79 · 95% CI 0.66 to 0.93Ratio of FF/VI 100/25mcg Vs Placebo for Day 14, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.67 · 95% CI 0.56 to 0.79Ratio of FF/VI 100/25mcg Vs Placebo for Day 14, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.79 · 95% CI 0.66 to 0.93Ratio of FF/VI 100/25mcg Vs Placebo for Day 15, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.79 · 95% CI 0.66 to 0.94Ratio of FF/VI 100/25mcg Vs Placebo for Day 15, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.74 · 95% CI 0.62 to 0.87Ratio of FF/VI 100/25mcg Vs Placebo for Day 16, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.73 · 95% CI 0.61 to 0.86Ratio of FF/VI 100/25mcg Vs Placebo for Day 16, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.77 · 95% CI 0.65 to 0.91Ratio of FF/VI 100/25mcg Vs Placebo for Day 17, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.81 · 95% CI 0.65 to 1.01Ratio of FF/VI 100/25mcg Vs Placebo for Day 17, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.77 · 95% CI 0.61 to 0.96Ratio of FF/VI 100/25mcg Vs Placebo for Day 18, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.77 · 95% CI 0.59 to 1.00Ratio of FF/VI 100/25mcg Vs Placebo for Day 18, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.81 · 95% CI 0.63 to 1.05Ratio of FF/VI 100/25mcg Vs Placebo for Day 19, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.72 · 95% CI 0.52 to 1.00Ratio of FF/VI 100/25mcg Vs Placebo for Day 19, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.78 · 95% CI 0.56 to 1.09Ratio of FF/VI 100/25mcg Vs Placebo for Day 20, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.78 · 95% CI 0.53 to 1.14Ratio of FF/VI 100/25mcg Vs Placebo for Day 20, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.85 · 95% CI 0.59 to 1.22Ratio of FF/VI 100/25mcg Vs Placebo for Day 21, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.75 · 95% CI 0.50 to 1.13Ratio of FF/VI 100/25mcg Vs Placebo for Day 21, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.83 · 95% CI 0.55 to 1.25Ratio of FF/VI 100/25mcg Vs Placebo for Day 22, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.77 · 95% CI 0.51 to 1.16Ratio of FF/VI 100/25mcg Vs Placebo for Day 22, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.99 · 95% CI 0.66 to 1.49Ratio of FF/VI 100/25mcg Vs Placebo for Day 23, AM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.67 · 95% CI 0.29 to 1.51Ratio of FF/VI 100/25mcg Vs Placebo for Day 23, PM
  • Placebo vs FF/VI 100/25mcg · Ratio: 0.72 · 95% CI 0.32 to 1.64Ratio of FF/VI 100/25mcg Vs Placebo for Day 24, AM
SecondaryChange From Baseline in FeNO Over the FF/VI Treatment Period

In participants with asthma the FeNO is a non-invasive marker of airway inflammation. The FeNO was measured by the participants AM (pre-dose) and PM on Day -7 and all the way through Day 29 of each treatment period. The measurements were recorded using Niox Vero device provided at the site. These FeNO measurements were done throughout the treatment period. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.

Time frame:
Baseline and up to Day 29 in each treatment period
Reported as:
Mean · Parts per billion
Change From Baseline in FeNO Over the FF/VI Treatment Period
Parts per billionPlaceboFF/VI 100/25mcg
Day 1, AM (n=27,27)1.9 ± 24.39-63.3 ± 45.47
Day 1, PM (n=27,27)-0.5 ± 24.55-68.5 ± 49.07
Day 2, AM (n=27,27)1.3 ± 27.67-63.5 ± 53.63
Day 2, PM (n=27,27)-3.1 ± 24.64-66.1 ± 48.26
Day 3, AM (n=27,27)-0.8 ± 25.07-56.6 ± 53.97
Day 3, PM (n=27,27)-7.9 ± 21.18-59.8 ± 47.32
Day 4, AM (n=27,27)1.2 ± 33.27-48.6 ± 50.54
Day 4, PM (n=27,27)-11.6 ± 17.93-51.5 ± 42.12
Day 5, AM (n=27,27)-15.3 ± 22.49-48.9 ± 47.09
Day 5, PM (n=26,26)-22.1 ± 19.45-54.0 ± 45.00
Day 6, AM (n=26,26)-17.6 ± 24.37-47.1 ± 42.19
Day 6, PM (n=24,26)-19.4 ± 25.76-54.0 ± 43.96
Day 7, AM (n=27,27)-15.4 ± 24.26-50.0 ± 43.19
Day 7, PM (n=25,25)-19.9 ± 25.92-46.4 ± 42.73
Day 8, AM (n=25,27)-14.2 ± 30.00-42.7 ± 44.14
Day 8, PM (n=27,26)-15.3 ± 24.70-46.1 ± 40.39
Day 9, AM (n=27,27)-5.7 ± 29.23-40.1 ± 37.45
Day 9, PM (n=27,27)-5.3 ± 23.53-38.7 ± 40.36
Day 10, AM (n=24,26)4.1 ± 27.86-31.6 ± 31.50
Day 10, PM (n=27,27)3.8 ± 28.99-32.8 ± 37.47
Day 11, AM (n=26,26)12.8 ± 31.82-23.8 ± 39.65
Day 11, PM (n=27,27)6.2 ± 34.03-26.4 ± 41.33
Day 12, AM (n=27,27)3.1 ± 24.79-25.7 ± 36.64
Day 12, PM (n=27,27)1.3 ± 25.08-29.4 ± 37.19
Day 13, AM (n=27,25)8.3 ± 35.47-23.3 ± 30.09
Day 13, PM (n=25,25)-1.6 ± 38.12-26.2 ± 39.97
Day 14, AM (n=26,27)4.7 ± 45.42-23.5 ± 38.84
Day 14, PM (n=25,26)-3.4 ± 42.26-30.9 ± 43.69
Day 15, AM (n=26,26)-1.6 ± 47.88-25.8 ± 37.76
Day 15, PM (n=25,25)-3.7 ± 49.33-27.9 ± 43.14
Day 16, AM (n=26,27)3.7 ± 48.00-26.7 ± 43.16
Day 16, PM (n=26,27)4.5 ± 37.40-26.6 ± 43.37
Day 17, AM (n=25,26)6.1 ± 42.81-20.9 ± 39.31
Day 17, PM (n=18,16)-8.5 ± 29.54-19.6 ± 48.58
Day 18, AM (n=17,14)-7.5 ± 32.10-27.3 ± 44.36
Day 18, PM (n=14,10)-6.2 ± 23.93-38.3 ± 42.90
Day 19, AM (n=14,10)-2.8 ± 27.47-30.7 ± 50.03
Day 19, PM (n=12,6)-9.3 ± 24.19-52.2 ± 49.82
Day 20, AM (n=12,6)0.1 ± 27.71-40.2 ± 46.27
Day 20, PM (n=7,5)-8.7 ± 21.68-59.0 ± 63.82
Day 21, AM (n=7,6)-6.6 ± 24.08-32.7 ± 56.23
Day 21, PM (n=7,5)-3.0 ± 25.83-51.2 ± 58.37
Day 22, AM (n=6,5)-7.5 ± 27.54-37.0 ± 66.25
Day 22, PM (n=6,5)-11.5 ± 27.52-51.8 ± 63.96
Day 23, AM (n=7,5)-0.6 ± 29.53-37.0 ± 71.04
Day 23, PM (n=2,1)-0.5 ± 54.450.0 ± NA
Day 24, AM (n=2,1)2.0 ± 59.4013.0 ± NA
Day 24, PM (n=1,1)-24.0 ± NA-8.0 ± NA
Day 25, AM (n=1,0)-33.0 ± NA—
Day 26, PM (n=0,1)—-1.0 ± NA
Day 28, AM (n=0,1)—4.0 ± NA
Day 28, PM (n=0,1)—-21.0 ± NA
Day 29, AM (n=0,1)—-8.0 ± NA
SecondaryChange From Baseline in Peak Expiratory Flow (PEF) During Treatment and Following Cessation of Repeat Dose Treatment With FF/VI

The PEF is a lung function evaluation assessed using a PEF meter. It was defined as the maximum amount of air exhaled during forced exhalation with lungs fully inflated. For PEF measurements the best of the 3 recordings were recorded AM and PM (i.e every 12 hours), from Day-7 through to Day 29 of TP1, and then from Day 1 of TP2 through to the (29). Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.

Time frame:
Baseline and up to Day 29 in TP1; Baseline and up to follow up (Day 29) in TP2
Reported as:
Mean · Liter per minute
Change From Baseline in Peak Expiratory Flow (PEF) During Treatment and Following Cessation of Repeat Dose Treatment With FF/VI
Liter per minutePlaceboFF/VI 100/25mcg
Day 1, AM (n=27,27)-1.0 ± 67.1144.6 ± 55.54
Day 1, PM (n=27,27)17.4 ± 69.5954.5 ± 63.23
Day 2, AM (n=27,27)5.1 ± 61.5032.4 ± 55.35
Day 2, PM (n=27,27)16.6 ± 74.0237.2 ± 53.42
Day 3, AM (n=27,27)9.0 ± 58.4924.3 ± 58.56
Day 3, PM (n=27,27)20.4 ± 69.1047.3 ± 52.80
Day 4, AM (n=26,26)18.3 ± 61.6328.8 ± 54.42
Day 4, PM (n=27,27)36.0 ± 85.6243.9 ± 56.01
Day 5, AM (n=27,26)19.7 ± 61.2825.4 ± 49.86
Day 5, PM (n=26,27)21.5 ± 75.9430.9 ± 49.67
Day 6, AM (n=25,26)-0.4 ± 69.894.1 ± 61.63
Day 6, PM (n=24,26)11.3 ± 75.2628.5 ± 52.75
Day 7, AM (n=27,27)11.5 ± 71.9717.0 ± 55.89
Day 7, PM (n=24,26)11.8 ± 75.3321.8 ± 55.70
Day 8, AM (n=27,27)-1.6 ± 73.802.6 ± 51.94
Day 8, PM (n=27,27)13.1 ± 61.799.1 ± 56.68
Day 9, AM (n=27,26)-7.2 ± 80.69-14.7 ± 74.06
Day 9, PM (n=27,27)9.1 ± 73.71-1.7 ± 58.12
Day 10, AM (n=26,26)-19.6 ± 76.63-19.9 ± 68.55
Day 10, PM (n=27,26)-1.7 ± 84.6412.6 ± 52.16
Day 11, AM (n=26,27)-12.8 ± 74.84-12.3 ± 56.24
Day 11, PM (n=27,27)15.8 ± 76.76-7.3 ± 63.12
Day 12, AM (n=24,26)-11.0 ± 83.14-23.5 ± 64.35
Day 12, PM (n=26,27)-2.4 ± 71.17-5.9 ± 66.19
Day 13, AM (n=27,26)-20.6 ± 77.50-35.1 ± 67.19
Day 13, PM (n=25,26)17.0 ± 104.76-13.0 ± 61.78
Day 14, AM (n=25,25)-31.5 ± 77.48-13.6 ± 65.25
Day 14, PM (n=25,27)-0.8 ± 76.69-1.6 ± 58.26
Day 15, AM (n=25,27)-17.4 ± 59.88-20.4 ± 58.86
Day 15, PM (n=25,25)-15.0 ± 67.65-7.8 ± 64.72
Day 16, AM (n=25,26)-27.0 ± 66.70-30.2 ± 75.78
Day 16, PM (n=26,26)-8.1 ± 74.860.7 ± 60.72
Day 17, AM (n=26,26)-23.4 ± 73.32-4.7 ± 65.85
Day 17, PM (n=18,16)10.6 ± 86.608.7 ± 62.33
Day 18, AM (n=17,14)-14.2 ± 79.963.8 ± 71.50
Day 18, PM (n=14,10)-8.9 ± 90.2529.6 ± 64.62
Day 19, AM (n=14,10)-11.4 ± 91.61-0.1 ± 70.24
Day 19, PM (n=12,6)2.3 ± 102.7627.7 ± 61.49
Day 20, AM (n=12,6)-8.5 ± 81.09-10.5 ± 71.92
Day 20, PM (n=7,5)-27.7 ± 46.0326.6 ± 49.22
Day 21, AM (n=7,6)-43.3 ± 56.8517.8 ± 78.20
Day 21, PM (n=6,4)-16.7 ± 73.86-19.8 ± 32.62
Day 22, AM (n=5,5)-48.4 ± 40.28-11.0 ± 103.22
Day 22, PM (n=6,5)-56.8 ± 46.23-2.0 ± 91.29
Day 23, AM (n=6,5)-15.0 ± 50.6211.4 ± 53.62
Day 23, PM (n=2,1)-53.0 ± 1.411.0 ± NA
Day 24, AM (n=2,1)-23.0 ± 25.4674.0 ± NA
Day 24, PM (n=1,1)-50.0 ± NA15.0 ± NA
Day 25, AM (n=1,0)-31.0 ± NA—
Day 26, PM (n=0,1)—-62.0 ± NA
Day 27, AM (n=0,1)—82.0 ± NA
Day 28, AM (n=0,1)—-42.0 ± NA
Day 29, AM (n=0,1)—6.0 ± NA
Statistical analysis
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 45.86 · 95% CI 23.69 to 68.03Difference of FF/VI 100/25mcg Vs Placebo for Day 1, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 45.37 · 95% CI 23.20 to 67.55Difference of FF/VI 100/25mcg Vs Placebo for Day 1, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 34.03 · 95% CI 11.86 to 56.21Difference of FF/VI 100/25mcg Vs Placebo for Day 2, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 31.56 · 95% CI 9.38 to 53.73Difference of FF/VI 100/25mcg Vs Placebo for Day 2, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 22.86 · 95% CI 0.68 to 45.03Difference of FF/VI 100/25mcg Vs Placebo for Day 3, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 36.94 · 95% CI 14.77 to 59.12Difference of FF/VI 100/25mcg Vs Placebo for Day 3, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 19.33 · 95% CI -3.00 to 41.66Difference of FF/VI 100/25mcg Vs Placebo for Day 4, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 20.85 · 95% CI -1.32 to 43.03Difference of FF/VI 100/25mcg Vs Placebo for Day 4, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 16.82 · 95% CI -5.47 to 39.11Difference of FF/VI 100/25mcg Vs Placebo for Day 5, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 21.86 · 95% CI -0.41 to 44.14Difference of FF/VI 100/25mcg Vs Placebo for Day 5, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 13.05 · 95% CI -9.57 to 35.67Difference of FF/VI 100/25mcg Vs Placebo for Day 6, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 28.68 · 95% CI 5.38 to 51.98Difference of FF/VI 100/25mcg Vs Placebo for Day 6, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 17.09 · 95% CI -5.08 to 39.26Difference of FF/VI 100/25mcg Vs Placebo for Day 7, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 23.61 · 95% CI 0.28 to 46.94Difference of FF/VI 100/25mcg Vs Placebo for Day 7, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 12.87 · 95% CI -9.30 to 35.05Difference of FF/VI 100/25mcg Vs Placebo for Day 8, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 7.50 · 95% CI -14.67 to 29.68Difference of FF/VI 100/25mcg Vs Placebo for Day 8, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 3.32 · 95% CI -19.11 to 25.74Difference of FF/VI 100/25mcg Vs Placebo for Day 9, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 3.83 · 95% CI -18.34 to 26.00Difference of FF/VI 100/25mcg Vs Placebo for Day 9, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 11.36 · 95% CI -11.11 to 33.82Difference of FF/VI 100/25mcg Vs Placebo for Day 10, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 27.73 · 95% CI 5.43 to 50.03Difference of FF/VI 100/25mcg Vs Placebo for Day 10, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 14.71 · 95% CI -7.57 to 36.98Difference of FF/VI 100/25mcg Vs Placebo for Day 11, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): -6.62 · 95% CI -28.80 to 15.55Difference of FF/VI 100/25mcg Vs Placebo for Day 11, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 4.36 · 95% CI -18.39 to 27.11Difference of FF/VI 100/25mcg Vs Placebo for Day 12, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 8.29 · 95% CI -13.99 to 30.57Difference of FF/VI 100/25mcg Vs Placebo for Day 12, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.64 · 95% CI -21.64 to 22.92Difference of FF/VI 100/25mcg Vs Placebo for Day 13, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): -6.88 · 95% CI -29.96 to 16.19Difference of FF/VI 100/25mcg Vs Placebo for Day 13, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 28.45 · 95% CI 5.76 to 51.13Difference of FF/VI 100/25mcg Vs Placebo for Day 14, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 12.31 · 95% CI -10.13 to 34.74Difference of FF/VI 100/25mcg Vs Placebo for Day 14, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 4.10 · 95% CI -18.16 to 26.36Difference of FF/VI 100/25mcg Vs Placebo for Day 15, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 18.87 · 95% CI -3.89 to 41.63Difference of FF/VI 100/25mcg Vs Placebo for Day 15, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 6.35 · 95% CI -16.17 to 28.88Difference of FF/VI 100/25mcg Vs Placebo for Day 16, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 19.07 · 95% CI -3.27 to 41.41Difference of FF/VI 100/25mcg Vs Placebo for Day 16, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 29.51 · 95% CI 6.87 to 52.15Difference of FF/VI 100/25mcg Vs Placebo for Day 17, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 9.64 · 95% CI -17.91 to 37.19Difference of FF/VI 100/25mcg Vs Placebo for Day 17, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 24.77 · 95% CI -4.20 to 53.73Difference of FF/VI 100/25mcg Vs Placebo for Day 18, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 47.04 · 95% CI 14.63 to 79.45Difference of FF/VI 100/25mcg Vs Placebo for Day 18, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 20.11 · 95% CI -12.30 to 52.52Difference of FF/VI 100/25mcg Vs Placebo for Day 19, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 25.13 · 95% CI -15.02 to 65.27Difference of FF/VI 100/25mcg Vs Placebo for Day 19, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): -7.89 · 95% CI -48.04 to 32.25Difference of FF/VI 100/25mcg Vs Placebo for Day 20, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 8.51 · 95% CI -37.22 to 54.25Difference of FF/VI 100/25mcg Vs Placebo for Day 20, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 15.08 · 95% CI -28.50 to 58.67Difference of FF/VI 100/25mcg Vs Placebo for Day 21, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 5.19 · 95% CI -45.35 to 55.73Difference of FF/VI 100/25mcg Vs Placebo for Day 21, PM
SecondaryChange From Baseline in Forced Expiratory Volume in One Second (FEV1) Pre-treatment and for up to 7 Days After Cessation of Repeat Dose Treatment With FF/VI

FEV1 is defined as the maximal amount of air which can be exhaled forcefully in one second. Three technically acceptable FEV1 measurements were made using a spirometer, and were measured on pre-dose on Day 1, taken pre-dose on Day 14 and every morning and evening until Day 19, and in the morning on Day 21. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant.

Time frame:
Baseline every morning and evening until Day 21 of each treatment period
Reported as:
Mean · Liter
Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Pre-treatment and for up to 7 Days After Cessation of Repeat Dose Treatment With FF/VI
LiterPlaceboFF/VI 100/25mcg
Day 1, AM0.036 ± 0.41690.361 ± 0.3135
Day 1, PM0.180 ± 0.31050.383 ± 0.3151
Day 2, AM0.073 ± 0.39530.331 ± 0.2739
Day 2,PM0.200 ± 0.39020.369 ± 0.3166
Day 3,AM0.084 ± 0.36680.271 ± 0.2967
Day 3,PM0.213 ± 0.38400.319 ± 0.3256
Day 4, AM0.092 ± 0.38700.241 ± 0.2913
Day 4, PM0.221 ± 0.41870.301 ± 0.3163
Day 5, AM0.197 ± 0.33750.207 ± 0.2498
Day 7, AM0.124 ± 0.37530.102 ± 0.3317
Day 21, AM0.082 ± 0.32100.004 ± 0.2670
Statistical analysis
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.36 · 95% CI 0.26 to 0.46Difference of FF/VI 100/25mcg Vs Placebo for Day 1, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.26 · 95% CI 0.16 to 0.36Difference of FF/VI 100/25mcg Vs Placebo for Day 1, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.34 · 95% CI 0.24 to 0.44Difference of FF/VI 100/25mcg Vs Placebo for Day 2, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.24 · 95% CI 0.14 to 0.34Difference of FF/VI 100/25mcg Vs Placebo for Day 2, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.26 · 95% CI 0.16 to 0.36Difference of FF/VI 100/25mcg Vs Placebo for Day 3, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.18 · 95% CI 0.08 to 0.28Difference of FF/VI 100/25mcg Vs Placebo for Day 3, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.24 · 95% CI 0.14 to 0.34Difference of FF/VI 100/25mcg Vs Placebo for Day 4, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.17 · 95% CI 0.07 to 0.27Difference of FF/VI 100/25mcg Vs Placebo for Day 4, PM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.07 · 95% CI -0.03 to 0.17Difference of FF/VI 100/25mcg Vs Placebo for Day 5, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.04 · 95% CI -0.06 to 0.14Difference of FF/VI 100/25mcg Vs Placebo for Day 7, AM
  • Placebo vs FF/VI 100/25mcg · Mean difference (net): 0.03 · 95% CI -0.07 to 0.13Difference of FF/VI 100/25mcg Vs Placebo for Day 21, AM

Adverse events

Collected over All the Serious adverse events (SAEs) and Adverse events (AEs) from Day 1 to upto Day 35 in each period (Total 70 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/27 (0%)0/27 (0%)10/27 (37%)
FF/VI 100/25mcg0/27 (0%)0/27 (0%)14/27 (51.9%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboFF/VI 100/25mcg
Viral upper respiratory tract infectionInfections and infestations5/277/27
Back painMusculoskeletal and connective tissue disorders2/270/27
Musculoskeletal painMusculoskeletal and connective tissue disorders0/272/27
EpistaxisRespiratory, thoracic and mediastinal disorders0/272/27
OrchitisInfections and infestations1/270/27
Urinary tract infectionInfections and infestations1/270/27
Viral pharyngitisInfections and infestations0/271/27
Neck painMusculoskeletal and connective tissue disorders0/271/27
Pain in extremityMusculoskeletal and connective tissue disorders0/271/27
CoughRespiratory, thoracic and mediastinal disorders0/271/27

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Total (Placebo+FF/VI 100/25mcg)
Mean24.5 ± 8.14
Sex: Female, Male
Sex: Female, Male(Participants)Total (Placebo+FF/VI 100/25mcg)
Female10
Male17
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Total (Placebo+FF/VI 100/25mcg)
White21
Asian and White1
Native Hawaiin or other Pacific Islander and White5
08

Study locations

1 site
  • GSK Investigational Site
    Newtown, Wellington, 6021, New Zealand
09

References and documents

Publications

  • Daley-Yates P, Keppler B, Baines A, Bardsley G, Fingleton J. Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial. Respir Res. 2022 Sep 20;23(1):258. doi: 10.1186/s12931-022-02164-w. PubMed 36127726 ↗
  • Bardsley G, Daley-Yates P, Baines A, Kempsford R, Williams M, Mallon T, Braithwaite I, Riddell K, Joshi S, Bareille P, Beasley R, Fingleton J; study team. Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial. Respir Res. 2018 Jul 13;19(1):133. doi: 10.1186/s12931-018-0836-6. PubMed 30001712 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Feb 2017, 9 months.

Results were first posted in Aug 2018, 1 year 6 months after primary completion.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 9 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2016
First posted
Mar 17, 2016
StartActual
Apr 29, 2016
Primary completionActual
Feb 21, 2017
CompletionActual
Feb 21, 2017
Results first posted
Aug 28, 2018
Last update
Aug 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02712047
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
Apr 29, 2016
Primary completion
Feb 21, 2017
Completion
Feb 21, 2017
Results posted
Aug 28, 2018
Last update
Aug 28, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion